The Galien – MedStartUp Awards: ProtecSom OptimHal nominee in two categories

The Galien foundation, a true catalyst for the development of health technologies, pairs every year with Business France to encourage, recognize and reward transatlantic partnerships projects.

ProtecSom-OptimHal a finalist in two categories

Since 2014, the MedStartUp Awards honour innovation, scientific excellence, and commercial potential of French-American projects. Preselected in 2016, the Laboratoire ProtecSom-OptimHal’s project is the only one to be selected as one of the 3 finalists in two categories:


  • Best Use of Health Patient Engagement Technologies
  • Best Collaboration or Partnership with Academia Leading to a Breakthrough Solution

DigitHal® enhances patients technique and observance

The nominated project, DigitHal®, by providing real time data on patient’s drug inhalation, intends to enhance technique and observance, parameters that are essentials, yet often lacking. OptimHal®’s new device will therefore provide a more comprehensive solution to the administration and monitoring of inhaled treatments.


ProtecSom-OptimHal, the wish to generate reel progress for patients and caretakers

This nomination is, in itself, a recognition of the innovative nature of the Laboratoire ProtecSom-OptimHal, that has since 2003 consistently proposed new devices, always with the wish to generate reel progress for patients and caretakers. It also validates the relevance of our broad partnership policy, demonstrated here with two collaborators:


  • Pr Bruce Rubin and the Virginia Commonwealth University, renowned throughout the world for their knowledge of inhaled treatment and pediatric medicine.
  • L’association pulmonaire du Québec, founded in 1938, a non-profit involved with the promotion of respiratory health and prevention of pulmonary diseases through research and education.

The winners will be selected by a world renown scientific committee and announced on October 2017, 26th in New York during the MedStartUp Days.

Share this article